Carisma Therapeutics, Inc.
Other OTCTotal Valuation
Carisma Therapeutics, Inc. carries a market capitalization of 213,410.00, placing it among publicly traded companies globally. Its enterprise value stands at 9.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 213,410.00 |
| Enterprise Value | 9.43M |
Share Statistics
Carisma Therapeutics, Inc. currently has 41.79M shares outstanding.
| Shares Outstanding | 41.79M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Carisma Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 1.42. The price-to-sales ratio is 0.22, and the price-to-book ratio stands at -0.04.
| PE Ratio | 1.42 |
| PS Ratio | 0.22 |
| PB Ratio | -0.04 |
| P/TBV Ratio | -13.20 |
| P/FCF Ratio | -0.51 |
| P/OCF Ratio | -0.51 |
Enterprise Valuation
The EV/Sales ratio of 0.18 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 0.87 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.18 |
| EV / EBITDA | 0.77 |
| EV / EBIT | 0.87 |
| EV / FCF | N/A |
Financial Position
Carisma Therapeutics, Inc. maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.86 |
| Quick Ratio | 0.65 |
| Debt / Equity | -87.89 |
| Debt / EBITDA | 0.06 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 33.09 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -2.85 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Carisma Therapeutics, Inc.'s stock has declined approximately -98.67739% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -98.67739% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Carisma Therapeutics, Inc. generated 52.63M in revenue and converted that into 8.04M in net income, yielding earnings per share of 0.19. EBITDA reached 12.18M, while operating income came in at 10.85M.
| Revenue | 52.63M |
| Gross Profit | N/A |
| Operating Income | 10.85M |
| Pretax Income | 8.04M |
| Net Income | 8.04M |
| EBITDA | 12.18M |
| EBIT | 10.85M |
| Earnings Per Share (EPS) | 0.19 |
Balance Sheet
Carisma Therapeutics, Inc. holds 2.78M in cash and equivalents against 762,000.00 in total debt, resulting in a net debt position of -2.78M. Total book value stands at -279.86M, with working capital of -942,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 2.78M |
| Total Debt | 762,000.00 |
| Net Debt | -2.78M |
| Equity (Book Value) | -279.86M |
| Book Value Per Share | -6.70 |
| Working Capital | -942,000.00 |
Cash Flow
Carisma Therapeutics, Inc. produced -22.41M in operating cash flow over the past twelve months.
| Operating Cash Flow | -22.41M |
| Capital Expenditures | N/A |
| Free Cash Flow | -22.41M |
| FCF Per Share | -0.54 |
Margins
Carisma Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 20.61 and net profit margin of 15.28 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | 20.61 |
| Pretax Margin | 15.28 |
| Profit Margin | 15.28 |
| EBITDA Margin | 23.14 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 20.75 |
| FCF Yield | -195.55 |
Stock Splits
Carisma Therapeutics, Inc.'s most recent stock split took place on March 8, 2023 with a 20:1 split ratio.
| Last Split Date | 3/8/2023 |
| Split Ratio | 20:1 |
Scores
Carisma Therapeutics, Inc. posts an Altman Z-Score of -45.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -45.54 |